This study examines how well a new drug called itepekimab works for people with chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a condition where the nose and sinuses are inflamed, causing stuffiness and sometimes, loss of smell. The study compares itepekimab to a placebo (a fake treatment) to see how effective it is when added to standard nasal sprays.

• The study lasts up to 76 weeks in total, with 52 weeks of treatment.
• There will be 9 visits to the study site and 20 more through phone or home visits.
• Participants must be 18 or older and have had CRSwNP for at least a year.

To join, participants should not have certain serious health conditions, should not smoke, and must not be allergic to the study drug. Women must not be pregnant or nursing, and if of childbearing age, should use effective birth control. The study aims to find out if itepekimab can help reduce symptoms like congestion and loss of smell caused by nasal polyps.